Cellectar Biosciences, Inc. Ttl Fee Amt
Cellectar Biosciences, Inc. (CLRB) had Ttl Fee Amt of $21.13 thousand as of 2026-05-29, per its S-1/A filed 2026-05-29.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-05-29
- 2026-05-29: Ttl Fee Amt $21.13K.
- 2026-05-19: Ttl Fee Amt $20.79K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-05-29 | $21.13K S-1/A · filed 2026-05-29 |
| 2026-05-19 | $20.79K S-1 · filed 2026-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |